The Labyrinth of Product Development and Regulatory Approvals in Liquid Biopsy Diagnostics
The evolution of chemistries and instrument platforms for next‐generation sequencing has led to sequencing of genomic variants in both tumor biopsies as well as in circulating tumor cells (CTCs) and cell‐free DNA liquid biopsies. The transition of these analytical platforms into clinical ones has le...
Main Author: | Federico M. Goodsaid |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-09-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.12657 |
Similar Items
-
Cushing’s syndrome: diagnostic labyrinths
by: A. R. Volkova, et al.
Published: (2021-02-01) -
Liquid Biopsy, Diagnostic Imaging, and Future Synergies
by: Digumarthy, S.R, et al.
Published: (2022) -
DOMESTIC DEVELOPMENT IN THE LABYRINTH
by: Arnoldo Oscar, Delgado
Published: (2010-01-01) -
Factitious disorders in children: A diagnostic labyrinth of cases
by: Chinmoy Raj, et al.
Published: (2019-01-01) -
On the Regulatory Approval Pathway of Biosimilar Products
by: Jun Wang, et al.
Published: (2012-03-01)